Tiny PillBot enters clinical trials, paving the way for advanced microsurgery

Endiatx's PillBot, a tiny, swallowable robot designed to inspect gastrointestinal health, is entering clinical trials with hopes of FDA approval and a commercial launch by 2026.

This innovative device aims to revolutionize non-invasive endoscopies by using cameras and sensors to provide a quick look inside the stomach via telemedicine.

The PillBot, which requires no sedation and minimal fasting, uses patented multi-pumpjet propulsion to navigate the body, controlled remotely by doctors. It captures live video, illuminated by its own LED system, for later AI-enhanced analysis.

CEO Torrey Smith has personally demonstrated the PillBot over 40 times, showcasing its capabilities. Once swallowed, the PillBot passes through the gastrointestinal system within 24 hours.

Endiatx has raised $7 million in funding and plans to improve the video quality soon. The company aims to make the PillBot affordable, potentially available over-the-counter for about $50.

Endiatx is also developing the PillSurgeon, an advanced version of the PillBot, capable of performing tasks like polyp removal, microbiome sampling, bleeding cauterization, and biopsies.